date: 2017-08-10T08:28:34Z
pdf:PDFVersion: 1.5
pdf:docinfo:title: Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
xmp:CreatorTool: LaTeX with hyperref package
access_permission:can_print_degraded: true
subject: Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor everolimus proved effective when applied alone, but more effective when they were administered combined. Recently, both drugs were included in clinical trials, resulting in international clinical guidelines for the treatment of mRCC. In May 2016, lenvatinib was approved by the American Food and Drug Administration (FDA) for the use in combination with everolimus, as treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. A major problem of treating mRCC with lenvatinib and everolimus is the serious adverse event (AE) of arterial hypertension. During the treatment with everolimus and lenvatinib combined, 42% of the patients developed hypertension, while 10% of the patients treated with everolimus alone and 48% of the of the lenvatinib only treated patients developed hypertension. Lenvatinib carries warnings and precautions for hypertension, cardiac failure, and other adverse events. Therefore, careful monitoring of the patients is necessary.
dc:format: application/pdf; version=1.5
pdf:docinfo:creator_tool: LaTeX with hyperref package
access_permission:fill_in_form: true
pdf:encrypted: false
dc:title: Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
modified: 2017-08-10T08:28:34Z
cp:subject: Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor everolimus proved effective when applied alone, but more effective when they were administered combined. Recently, both drugs were included in clinical trials, resulting in international clinical guidelines for the treatment of mRCC. In May 2016, lenvatinib was approved by the American Food and Drug Administration (FDA) for the use in combination with everolimus, as treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. A major problem of treating mRCC with lenvatinib and everolimus is the serious adverse event (AE) of arterial hypertension. During the treatment with everolimus and lenvatinib combined, 42% of the patients developed hypertension, while 10% of the patients treated with everolimus alone and 48% of the of the lenvatinib only treated patients developed hypertension. Lenvatinib carries warnings and precautions for hypertension, cardiac failure, and other adverse events. Therefore, careful monitoring of the patients is necessary.
pdf:docinfo:subject: Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor everolimus proved effective when applied alone, but more effective when they were administered combined. Recently, both drugs were included in clinical trials, resulting in international clinical guidelines for the treatment of mRCC. In May 2016, lenvatinib was approved by the American Food and Drug Administration (FDA) for the use in combination with everolimus, as treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. A major problem of treating mRCC with lenvatinib and everolimus is the serious adverse event (AE) of arterial hypertension. During the treatment with everolimus and lenvatinib combined, 42% of the patients developed hypertension, while 10% of the patients treated with everolimus alone and 48% of the of the lenvatinib only treated patients developed hypertension. Lenvatinib carries warnings and precautions for hypertension, cardiac failure, and other adverse events. Therefore, careful monitoring of the patients is necessary.
pdf:docinfo:creator: Mathias Alrø Fichtner Bendtsen, Daniela Grimm, Johann Bauer, Markus Wehland, Petra Wise, Nils E. Magnusson, Manfred Infanger and Marcus Krüger
PTEX.Fullbanner: This is pdfTeX, Version 3.14159265-2.6-1.40.17 (TeX Live 2016/W32TeX) kpathsea version 6.2.2
meta:author: Mathias Alrø Fichtner Bendtsen, Daniela Grimm, Johann Bauer, Markus Wehland, Petra Wise, Nils E. Magnusson, Manfred Infanger and Marcus Krüger
trapped: False
meta:creation-date: 2017-08-10T08:28:34Z
created: 2017-08-10T08:28:34Z
access_permission:extract_for_accessibility: true
Creation-Date: 2017-08-10T08:28:34Z
Author: Mathias Alrø Fichtner Bendtsen, Daniela Grimm, Johann Bauer, Markus Wehland, Petra Wise, Nils E. Magnusson, Manfred Infanger and Marcus Krüger
producer: pdfTeX-1.40.17
pdf:docinfo:producer: pdfTeX-1.40.17
pdf:unmappedUnicodeCharsPerPage: 0
Keywords: metastatic renal cell carcinoma; lenvatinib; everolimus; hypertension; multikinase inhibitors; mTOR inhibitor; vascular endothelial growth factor
access_permission:modify_annotations: true
dc:creator: Mathias Alrø Fichtner Bendtsen, Daniela Grimm, Johann Bauer, Markus Wehland, Petra Wise, Nils E. Magnusson, Manfred Infanger and Marcus Krüger
dcterms:created: 2017-08-10T08:28:34Z
Last-Modified: 2017-08-10T08:28:34Z
dcterms:modified: 2017-08-10T08:28:34Z
title: Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
Last-Save-Date: 2017-08-10T08:28:34Z
pdf:docinfo:keywords: metastatic renal cell carcinoma; lenvatinib; everolimus; hypertension; multikinase inhibitors; mTOR inhibitor; vascular endothelial growth factor
pdf:docinfo:modified: 2017-08-10T08:28:34Z
meta:save-date: 2017-08-10T08:28:34Z
pdf:docinfo:custom:PTEX.Fullbanner: This is pdfTeX, Version 3.14159265-2.6-1.40.17 (TeX Live 2016/W32TeX) kpathsea version 6.2.2
Content-Type: application/pdf
X-Parsed-By: org.apache.tika.parser.DefaultParser
creator: Mathias Alrø Fichtner Bendtsen, Daniela Grimm, Johann Bauer, Markus Wehland, Petra Wise, Nils E. Magnusson, Manfred Infanger and Marcus Krüger
dc:subject: metastatic renal cell carcinoma; lenvatinib; everolimus; hypertension; multikinase inhibitors; mTOR inhibitor; vascular endothelial growth factor
access_permission:assemble_document: true
xmpTPg:NPages: 12
pdf:charsPerPage: 3026
access_permission:extract_content: true
access_permission:can_print: true
pdf:docinfo:trapped: False
meta:keyword: metastatic renal cell carcinoma; lenvatinib; everolimus; hypertension; multikinase inhibitors; mTOR inhibitor; vascular endothelial growth factor
access_permission:can_modify: true
pdf:docinfo:created: 2017-08-10T08:28:34Z